

Supplementary Table S1. Foundation One Medicine genomic testing results and targeted therapy recommendations for all patients evaluated by the MTB, organized by malignancy type.

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
AML	unknown	stable	low (2)	no significant findings; variants of unknown significance only	none			DOD 3/3/2020	BLM ERBB4 FHIT FLYWCH1 IKBKE MED12 MYST3 PLCG2 PTCH1 PTPN11 TET2 TP53 WDR90
AML	unknown	stable	low (0)	KRAS G12S NRAS Q61R ATRX W2139* BLMY736fs*5 RUNX1-FPL22 fusion RUNX1-MECOM fusion WT1 V379fs*71	Binimetinib Cobimetinib Trametinib 1 trial	AML16 IDA-FLAG Hydroxyurea 5/4/2020	Trametinib 1/28/2020 Gilteritinib 2/19/2020 d/c 5/4/2020	2/1/2020 DOD 6/7/2020	BLM C11ORF30 (EMSY) CHEK2 KMT2A (MLL) MYD88 NTRK3 S1PR2 SETD2
AML	unknown	stable	low (2)	CSF3R T618I	Ruxolitinib 8 trials				CD22 FGF14 FOXO3 MED12 NCOR2 RICTOR TSC1 TSC2 ZND217
AML	unknown	unknown	low (3)	NUP214-ABL1 fusion ATM R2598Q CDKN2A p16IKN4a I49T GATA1 splice site 220+1G>T RUNX1 truncation exon 2	Bosutinib Dasatinib Imatinib Nilotinib Ponatinib 4 trials ATM: Olaparib Rucaparib Niraparib 1 trial				
AML	unknown	stable	unknown	KMT2A (MLL-MLLT6 fusion) KMT2C (MLL3)	10 clinical trials				
AML	unknown	stable	low (1)	BRCA2 NPM1 KDM6A PTPN11	BRCA2 Niraparib Olaparib Rucaparib Talazoparib 1 trial NPM1 10 trials				
Angiosarcoma	**	**	low (3)	RAF1 AXIN1 A526V PDCD1LG2 (PD-L2) R70H PTPN6 H445fs*101 TP53 R248W	Trametinib Cobimetinib Sorafenib Regorafenib 4 trials				
Angiomyxoma	0%	stable	low (0)	APC loss	none				
B-ALL	0%	**	**	**sample failure**	**				
Chordoma	unknown	unknown	unknown	unable to reach pt for consent for tissue - sample failure on previous attempt					
Chordoma	0%	**	**	**sample failure**	**				
Chordoma	0%	**	**	**sample failure**	**				
Colon Adenocarcinoma	unknown	unknown	unknown	NF1 L2678_V2685>* TP53 P80fs*43 MYST3 NOTCH2 G929fs*2 PRKAR1A V164fs*5	NF1 Cetuximab Panitumumab Tremetinib 5 trials TP53 1 trial				BRCA2 CSF1R FGFR1 KDM5A MRE11A STK11
DLBCL	**	**	**	**sample failure**	**				
DSRCT	unknown	unknown	unknown	EWSR1-WT1 fusion CD36 L360*	4 trials	AEWS1031 EOT 2016			EPHA5 GRP124 TSC2
DSRCT	unknown	unknown	low (3)	AKT3 EWSR1-WT1 fusion	Everolimus Temsirolumis 8 trials	Salvage Chemo - Temozolomide/ Irinotecan		DOD 2/15/2017	CREBBP CTNNA1 DNM2 FAF1 FAM123B MLL3 MSH3 NOTCH2 NUP98 SYK TCF3 WT1
DSRCT	unknown	unknown	unknown	EWSR1-WT1 fusion PRKAR1A loss	4 trials				

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
Ewing's Sarcoma	unknown	unknown	unknown	EWSR1-FL11 fusion	Everolimus Temozolimus 5 trials			DOD 8/13/2016	
Ewing's Sarcoma	0%	stable	low (2)	EWSR1-FL11 fusion TP63 T566M	4 trials	AEWS0031 EOT 12/2019			CBL EGFR FANCL HGF KDM2B LRP1B MAP3K7 PDCD11 PLCG2 PTCH1 SETD2 SPEN
Ewing's Sarcoma	unknown	stable	low (2)	RB1 loss	none	VCR/Doxo/CTX EOT 11/18/2019			CTEBP DAXX EPHA3 EPHB1 IGF1R IRF8 KMT2C (MLL3) MAF MYO18A NUP98 PTCH1 SETD2 SGK1
Ewing's Sarcoma	0%	stable	low (4)	CCND1 EWSR1-FL11 fusion (type 10/5) CDKN2A/B p16INK4a loss and p14ARF loss exons 2-3	Abemaciclib Palbociclib Ribociclib 11 trials				BCORL1 CPS1 HIST1H1C KMT2A (MLL) MAP3K1 MED12 MLH1 NCOR2 PTPN6 SETBP1 TSC1 TYK2
Ewing's Sarcoma	unknown	stable	low (4)	CCND1 CDK4 EWSR1-FL11 fusion (type 8/6) CKS1B EP300 P2310fs*44 MCL1 PDCD1	CCND1 Abemaciclib Palbociclib Ribociclib 10 trials CDK4 Palbociclib Ribociclib 10 trials EWSR1 7 trials				APH1A AR ARID1A BCL11B BLM BRIP1 DOT1L FGFR3 HSP90AA1 PLCG2 PTPN11 PTPN6 STAT6 YY1AP1 XNF703
Ewing's Sarcoma	0%	stable	low (0)	EWSR1-FL11 fusion CDKN2A/B loss MYS13	4 trials				CHEK2 FLYWCH1 IRS2 NOD1 PDGFRB RELN TSC1 ZNF703
Ewing's Sarcoma	1%	stable	low (0)	EWSR1 (FL11 fusion; type 2)	5 trials				CRKL EWSR1 KMT2C PDGFRA I543T SPEN TSC1
Ewings, Recurrent	1%	stable	low (0)	EWSR1	4 trials			12/1/2020	ATM ERG MLL2 RELN RUNX1
Ewings, Recurrent	0%	stable	low (0)	EWSR1 (FL11 fusion) CDKN2A/B loss (Same results w/KCS)	3 clinical trials				PRDM1 PRKDC RNF43
Fibrosarcoma	unknown	unknown	unknown	ETV6 ETV6-NTRK3 fusion DDKN2A p16INK4a R58* and p14ARF P721L	6 trials				
Germ Cell Tumor	unknown	unknown	unknown	KRAS G13D TP53 R249S	Trametinib Cobimetinib 6 trials				
Glioma (brain)	unknown	stable	unknown	HGF TCL1A TP53	5 trials				
Glomorus Tumor	1%	stable	low (2)	PDGFRB R561_E563>Q	Sunitinib 3 trials			7/1/2021	EPHA3 ERBB2 PCLO PDCD11 SETD2 TSC1 FLYWCH1 ROS1 HNF1A SETBP1
Granular Cell Tumor	0%	stable	low (2)	none	none				

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
HCC - Fibromellar	unknown	stable	low (2)	CDKN1B A121fs*24 JAK3	none				ARID1A ATR CIC JAK3 RPTOR SPTA1 ZNF217
Hepatoblastoma	0%	stable	low (1)	CTNNB1 D32, S29F	10 trials	AHEP1531 EOT 3/1/3031			AXL CREBBP LRP1B LRRK2 MAP3k1 MTOR PDGFRA D444H
Hepatoblastoma	0%	stable	low (2)	CTNNB1 G34V TP53 N263D	10 trials			1/1/2020	
Histiocytic Malignancy	20%	stable	low (4)	SETD2	none		Nivolumab 12/14/2020 Nivo + Ipilimumab 2/18/2021	Aug 2020, Oct 2020 March 2021 TCH Rare Tumor Board May 2021	BRIP1 DOT1L EGFR HDAC4 MCL1 MLL2 SMARCA1 WHSC1 (MMSET)
Hodgkins Lymphoma	unknown	unknown	unknown	None	none	Clofarabine - 2 cycles			
Inflammatory Myofibroblastic Tumor	50%	stable	low (1)	ALK TPM4-ALK fusion	Brigatinib Ceritinib Crizotinib Alectinib Lorlatinib 10 trials			6/1/2021	CUX1 IRS2 KDM6A PRKDC RNF43 SUZ12
LCH	unknown	unknown	unknown	MAP2K1 TBL1XR1	MAP2K1 Trametinib Selumetinib 2 trials	Ara-C Hydrocortisone			AXIN1 CIC FBXW7 GNAS KMT2C (MLL3) MYO18A TSC1
LCH	unknown	**	**	**sample failure**	**	LCH0115			
LCH	unknown	**	**	BRAF R506_K507insLLR	Trametinib Selumetinib	TXCH LCH0115 Cytarabine Arm			ARID1A CIC ECT2L FBX011 MAP3K1 MLL2 MYO18A NKX2-1 SVK TSC1
LCH	failed	failed	failed	BRAF	Binimetinib Cobimetinib Regorafenib Selumetinib Sorafenib Trametinib 2 trials			11/1/2020	
LCH	unknown	stable	low (0)	BRAF	Binimetinib Cobimetinib Dabrafenib Encorafenib Regorafenib Selumetinib Trametinib Vemurafenib 3 trials			11/1/2020	
LCH	unknown	unknown	unknown	MAP2K1 (KCS only results)					
LCH	unknown	stable	low (0)	BRAF V600E	Dabrafenib Dabrafenib + Trametinib Encorafenib + Binimetinib Regorafenib Selumetinib Trametinib Vemurafenib Vemurafenib + Cobimetinib				C11ORF30 (EMSY) MLL2 SPEN
LCH	unknown	stable	low (0)	MAP2K1 (MEK1) Q56P	Binimetinib Cobimetinib Trametinib 3 trials			3/1/2020	
LCH	unknown	stable	low (1)	MAP2K1 (MEK1) PASK	MAP2K1 (MEK1) Binimetinib Cobimetinib Selumetinib Trametinib 2 trials				APC CRLF2 P2RY8

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
Leiomyosarcoma	0%	stable	low (2)	PPFIBO1-ALK fusion CD36 N53fs*24 CDKN2A/B loss	Entrectinib Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib 10 trials	Gemcitabine & Taxotere (progressed after 2 cycles)	Ceritinib 3/2019; progression 2/2020; Lorlatinib 3/2020	6/1/2019, DOD 10/19/2020	
Leiomyosarcoma	5%	stable	low (3)	PPFIBP1-ALK fusion CD36 N53fs*24 CDKN2A/B p16INK4a R80* and p14ARF P94L - subclonal loss	Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib 10 trials				
Lung Adenocarcinoma	20%	stable	low (1)	ROS1 SDC4-ROS1 fusion	Brigatinib Ceritinib Crizotinib Entrectinib Lorlatinib 10 trials	benign			ATRX AXL DDR2 EPHB4 PPP2R1A PTCH1 RAD54L
Lymphoblastic Leukemia/ Lymphoma	unknown	stable	low (2)	CDKN2A/B CDKNEA loss exon 1 CDKN2B loss exon 2 MTOR S2215Y NT5C2 R367Q PAX5-PTPLAD2 fusion	none				
Lymphoma, lymph node anaplastic large cell	unknown	unknown	low (2)	NPM1-ALK fusion PIM1 amplification STAG2 rearrangement exon 5	Alectinib Brigatinib Ceritinib Crizotinib 5 trials				
Malignant Neoplasm	unknown	unknown	low (1)	none	none	ARST0531			BRCA2 CRLF2 ECT2L FAF1 MIB1 MSH3 NCOR2
Malignant Peripheral Nerve Sheath Tumor	0%	stable	intermediate (7)	NF1 splice site 4431-1G>A CDKN2A/B loss SUZ12 R196fs*15 TP53 R280K	Cobimetinib Trametinib 9 trials				ATM CTNNB1 DNM2 MAP3K6 ETV1 MSH2 MSH6 NFE2L2 NTRK1 RICTOR ROS1
Medulloblastoma	unknown	stable	low (0)	JAK1 R724L MLL2 E1207fs*4	none				FBXO11 GTSE1 LMO1 MYCN
Myofibroblastic Tumor	0%	unknown	unknown	ALK THBS1-ALK fusion	Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib Entrectinib 10 trials				
Osteosarcoma	0%	stable	unknown	ARAF C17orf39	Sorafenib 10 trials	AOST0331 EOT 1/27/2020		7/1/2020	BRCA2 CEBPA DDX3X EGFR FLCN KDM6A MAGED1 MAP2K4 MED12 MLL2 NOTCH2 RPTOR SMC3
Osteosarcoma	unknown	unknown	unknown	CDK4 RICTO C17orf39 CCND3 KDM4C amplification CDKN2A p16INK4a I49T DAXX loss	Palbociclib Ribociclib 8 trials	Ifos/VP16 EOT 2013 Pazopanib (salvage) 5/2/2016 d/c 8/29/2016 Doxil x 6 cycles Regorafenib 8/13/2018	Palbociclib 8/8/2017 x1 yr	DOD 2/8/2019	

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
									ABL1 APH1A ATM BIRC3 CBL CHEK1 EGFR ERG GPR124 KMT2A (MLL) LRRK2 PRKDC RASGEF1A RET RUNX1 SDHD SETBP1 U2AF1
Osteosarcoma	1%	stable	low (2)	RET MCL1 RAD21 TP53	2 trials				
Osteosarcoma	unknown	stable	low (2)	CDK8	none				
				AURKA GNAS LRP1B RAD21 ZNF217	2 trials				
Osteosarcoma	0%	stable	low (0)						
				CCNE1 RB1					
Osteosarcoma	unknown	stable	intermediate (6)	TP53	none				
				C17orf39 CCNE1 FLT1 S287F RB1 splice site 2450_2489+76del116 - subclonal					
Osteosarcoma	low (1%)	unknown	low (1)	TP53 rearrangement exon 2	none				
				MYC duplication exons 2-3 C17orf39 CCNE1 amplification - equivocal MAP2K4 rearrangement intron 6 RB1 A18fs*3 TP53 R248Q1	5 trials				
Osteosarcoma	0%	stable	unknown						
				KDR KIT PDGFRA AURKB CCND3 TP53 R290L - subclonal	KDR: Sunitinib 3 trials KIT: Imatinib Nilotinib Sorafenib Sunitinib 8 trials PDGFRA: Imatinib 3 trials				
Osteosarcoma	10%	stable	intermediate (12)						
				SUFU A25fs*23 DNM2 rearrangement intron 19	4 trials				
Osteosarcoma	0%	stable	low (3)						
Osteosarcoma	0%	**	**	**sample failure**	**				
				AKT2 AURKA AXL MYC RICTOR ARFRP1 C17orf39 CCNE1 CRKL FGF10 GNAS TP53 rearrangement intron 6	17 trials				
Osteosarcoma	0%	stable	low (3)						
				CDK4 AURKB C17orf39 CCND3 IGF1R NF2 loss exon 1 CDKN2A loss CDKN2B loss exons 1-2 FHIT loss exon 5 LRP1B loss exons 4-7	CDK4: Palbociclib Ribociclib 5 trials NF2: Everolimus Temozolimus 10 trials				
Osteosarcoma	unknown	unknown	low (3)						

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
Osteosarcoma	0%	stable	low (5)	KIT PDGFRA BCL2L2 KDR RB1 G310fs*8, inversion exon 8 TP53 splice site 993+1G>A	KIT Sorafenib Imatinib Nilotinib Sunitinib 10 trials PDGFRA Imatinib 2 trials				
Osteosarcoma	low (1%)	stable	low (4)	CDK4 BCL2L2 CCND3 GNAS NFKBIA FANCE truncation exon 10	Palbociclib Ribociclib 8 trials				
Osteosarcoma	0%	stable	low (3)	C17orf399 CCNE1 TP52 R342*	none				
Peritoneum Mesothelioma				BCL2 H20Q	2 trials				
Pre B-ALL	0%	stable	low (2)	TP53 V272M		AALL1131 Blinatumomab (d/c 5/4/2021) Inatumomab			
RCC	0%	stable	intermediate (7)	PIK3Ca E1037K CDKN2A/B p16INK4a and p14ARF R122Q KRI1-KEAP1 fusion TP53 splice site 415_560-14del213	Everolimus Temsirolimus 10 trials			7/1/2019	
RCC, recurrent	0%	stable	low (1)	TFE3 CDK2NA/B loss KDM5C loss	TFE3 Carbozantinib Sunitinib 10 trials			8/1/2020	
Rhabdoid Tumor	0%	stable	low (6)	SMARCB1 loss	razemestostat 10 trials			6/1/2020	
Rhabdoid Tumor	unknown	unknown	unknown	SMARCB1 truncation intron 2 MAP3K7N463S	4 trials			DOD 3/16/2016	BRCA2 CDKN2A CREBBP MLL2 MYO18A TSC2
RMS	unknown	unknown	low (2)	ASXL1-SBNO2 rearrangement RB1 loss exons 2-27 TP53 T329fs*8 ZND703	none	ARST0331 ARST0921 EOT 10/2018			APC DOT1L MLL2 MTOR
RMS	0%	stable	low (4)	CDK4 PAX3-FOXO1 fusion	Palbociclib Ribociclib 10 trials	RMS13 ARST0921		5/1/2020 DOD 2/19/2021	ACTB CCT6B CUX1 JAK2 PBRM1 PCLO PRDM1
RMS	low (1%)	stable	low (3)	BCOR P1258fs*36 NOTCH1 M1737_Y1738insPPPPAQL HFM	none	RMS13 - stopped 9/2019 ARST1431 - 12/2019; NED 3 mon OT			BCORL1 GATA2 HDAC7 KEAP1 NOTCH1 SYK WDR90
RMS	unknown	unknown	unknown	NF1 S1329* MYC amplification ETV6 truncation exon 5 SUZ12 splice site 917+1G>A TP53 Q167_D184>H	NF1: Cobimetinib Trametinib 4 trials MYC: 3 trials	ARST0331 (12/2015 - completed) Relapse - ARST0921 (x2 cycles) Progression Salvage chemo 3/2016 (ifos/doxo) ARST0332		DOD 2/28/2017	ATRX AXL CD36 FANCL FHIT MYST3 P2RY8 PAG1 PCLO PIK3R1 POT1 PRKDC RAD21 RELN
RMS, Alveolar	0%	stable	low (2)	CDK4 PAX3-FOXO1 fusion	10 trials				BLM CD36 DOT1L FANCC FANCF FBXO11 FLT3 MTOR PCLO PLCG2 SETBP1 SPEN STAT6

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
RMS, Embryonal	0%	stable	low (3)	NF1 loss exons 4-8 FGFR1 CDKN2A/B loss MYST3 RAD21 ZNF703	NF1 Selumetinib Trametinib 16 trials	ARST0331		7/1/2021	AR L254V EBF1G501V GPR124 MRE11A D131N PAG1 PDGFRA E263A PRKDC L3900V RELN A150V RUNX1T1 TNFAIP3T647P TSC2 R1409W TUSC3
RMS, Embryonal	10%	stable	low (2)	MALT1 TP53	none			1/1/2021	BCL6 CRLF2 FBXO11 HDAC4 IGF1R LRP1B MSH2 MSH6 PASK SOX10 SYK WDR90
RMS, recurrent	0%	stable	low (0)	CDK4 MDM2 FOXO1 (COL4A4 fusion) FRS2 MYCL1 PAX3 (FOXO1 fusion)	CDK4: 10 trials MDM2: 7 trials				BRCA2
Sarcoma	0%	**	**	**sample failure**	**				
Sarcoma	0%	stable	low (3)	BCOR-CCNB3 fusion	none	ARST1321			AR MLH1
Sarcoma	unknown	unknown	unknown	NF2 truncation intron 13 PASK R451*	Everolimus Temsirolimus 4 trials	ARST (VAC/VI) progression 3/2018	Pembrolizumab 3/2018	DOD 8/11/2018	
Sarcoma	unknown	unknown	low (2)	none	none				BRCA2 CHEK2 CSF1R GTSE1 IRF4 MYST3 SMO
Sarcoma	0%	stable	intermediate (6)	EGFR duplication exons 18-25 PIK3CA G1049R - subclonal ARID1A M923fs*13	EGFR: Afatinib Erlotinib Gefitinib Osimertinib Cetuximab Lapatinib Panitumumab 7 trials PIK3CA: Temsirolimus Everolimus 10 trials				
Sarcoma	30%	stable	low (2)	PDGFRB R561C PAX 5 loss TNFAIP3 A586T	PDGFR: Sunitinib 1 trial			8/1/2019	
Sarcoma	0%	stable	low (1)	EGFR duplication exons 18-25 CDKN2A/B loss SDHA A437fs*45	Afatinib Dacomitinib Erlotinib Gefitinib Osimertinib 8 trials				
Sarcoma	0%	stable	low (2)	none	none			12/1/2020	ARID2 ERBB2 EXOSC6 KMT2C(MLL3) MED12 NTRK3 RELN S1PR2 SPEN TCF3 TSC2 TSHR
Sarcoma	unknown	stable	low (2)	NOTCH1 A2279V	none				
Sarcoma	0%	stable	low (2)	BCOR-ITD	none				
Sarcoma	5%	stable	low (2)	MYC HMBOX1-NTRK3 fusion	11 trials				

Diagnosis	PD-L1	MS	TMB	Genomic Findings	Recommended Therapies & Trials	Traditional Tx	Targeted Tx	MTB date	VUS
Soft Tissue Fibromatosis	0%	stable	low (0)	none	none				VUS BRIP1 GNAS IGF1R JAK2 JAK3 ROS1
Soft Tissue Fibromatosis	0%	stable	low (4)	APC	none				
Squamous Cell Carcinoma	10%	stable	low (0)	INPP4B	none				AXIN1 FANCG FGF19 FLT3 GSK3B KDR PTPRO VHL
Synovial Sarcoma	0%	stable	low (1)	CDK4 SS18-SSX1 fusion MUTYH G382D	Palbociclib Ribociclib 10 trials				
Synovial Sarcoma	0%	stable	low (2)	SS18 SSX1 fusion	1 trial				ATRX E1464del BRSK1 P764A EP300 K1542E & Q2268del FAM123B P750S MKI67 T2509M
Synovial Sarcoma	0%	stable	low (2)	SS18-SSX1 fusion	1 trial				
Synovial Sarcoma	30%	stable	low (0)	SS18-SSX2 fusion KMT2C (MLL3) V884fs*29	NCT02638428 (SS18-SSX2) NCT02389309 (SS18-SSX2)				
T-ALL	unknown	stable	unknown	KRAS CDKN2A/B MET U2AF1 NOTCH1	KRAS Selumetinib Trametinib 1 trial				AURKB FGFR3 KEAP1 KMT2A (MLL) MAP3K1 NTSC2 PCLO SMARCA4 TSC1 WDR90
Teratoma	unknown	stable	low (1)	U2AF1 R156H	none				BIRC3 BRCA1 CDH1 ICK MLL2 MTOR MYST3 PCLO PLCG2 S1PR2 SOX10 STK11 TSC1
Wilms	0%	stable	low (1)	CTNNB1 S45Y	10 trials	DD4A EOT 6/26/2020			ALK CASP8 FUBP1 KMT2A (MLL) RBM10 RNF43 TEK TIPARP TSC1
Wilms	0%	stable	low (1)	FBXW7 SPOP TP53	FBXW7 Everolimus Temsilolimus			9/6/2021	CTNNB1 PCLO LRP1B ZNF703 MAP3K6 NOTCH1
Wilms	unknown	stable	low (4)	FAM123B R353* TP53 C176_P177insC	none				
Wilms	0%	stable	low (2)	BRCA1	Niraparib Olaparib Rucaparib Talazoparib 10 trials			3/21/2021	
Wilms	0%	stable	low (0)	POLE R1634H	none				